EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer
Technical Report,15 Aug 2012,14 Aug 2017
The Leland Stanford Junior University Stanford United States
Pagination or Media Count:
Stereotactic ablative radiotherapy SABR has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third-generation hypoxia PET agent, 18F-EF5,is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.
- Medicine and Medical Research